Tredje AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.34M | Sell |
10,676
-26,392
| -71% | -$3.32M | 0.01% | 306 |
|
|
2025
Q1 | $4.1M | Buy |
37,068
+27,704
| +296% | +$3.06M | 0.04% | 163 |
|
|
2024
Q4 | $1.28M | Sell |
9,364
-9,364
| -50% | -$1.28M | 0.01% | 356 |
|
|
2024
Q3 | $2.16M | Hold |
18,728
| – | – | 0.02% | 354 |
|
|
2024
Q2 | $2.58M | Sell |
18,728
-289
| -2% | -$39.8K | 0.02% | 306 |
|
|
2024
Q1 | $2.62M | Buy |
19,017
+3,557
| +23% | +$491K | 0.03% | 318 |
|
|
2023
Q4 | $2.04M | Sell |
15,460
-649
| -4% | -$85.5K | 0.03% | 376 |
|
|
2023
Q3 | $1.81M | Sell |
16,109
-1,494
| -8% | -$168K | 0.03% | 380 |
|
|
2023
Q2 | $1.66M | Sell |
17,603
-2,782
| -14% | -$262K | 0.02% | 422 |
|
|
2023
Q1 | $2.06M | Buy |
20,385
+1,051
| +5% | +$106K | 0.03% | 387 |
|
|
2022
Q4 | $2.31M | Sell |
19,334
-115
| -0.6% | -$13.7K | 0.04% | 341 |
|
|
2022
Q3 | $2.07M | Buy |
+19,449
| New | +$2.07M | 0.04% | 333 |
|